|
1.
|
Prat J: FIGO Committee on Gynecologic
Oncology: Staging classification for cancer of the ovary, fallopian
tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Clarke-Pearson DL: Clinical practice.
Screening for ovarian cancer. N Engl J Med. 361:170–177. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Covens A, Carey M, Bryson P, Verma S, Fung
Kee, Fung M and Johnston M: Systematic review of first-line
chemotherapy for newly diagnosed postoperative patients with stage
II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 85:71–80.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Parmar MK, Ledermann JA, Colombo N, du
Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W,
Torri V, et al: ICON and AGO Collaborators: Paclitaxel plus
platinum-based chemotherapy versus conventional platinum-based
chemotherapy in women with relapsed ovarian cancer: The
ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Alberts DS, Liu PY, Wilczynski SP, Clouser
MC, Lopez AM, Michelin DP, Lanzotti VJ and Markman M: Southwest
Oncology Group: Randomized trial of pegylated liposomal doxorubicin
(PLD) plus carboplatin versus carboplatin in platinum-sensitive
(PS) patients with recurrent epithelial ovarian or peritoneal
carcinoma after failure of initial platinum-based chemotherapy
(Southwest Oncology Group Protocol S0200). Gynecol Oncol.
108:90–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
O'Brien ME, Yau T, Coward J, Hughes S,
Papadopoulos P, Popat S, Norton A and Ashley S: Time and
chemotherapy treatment trends in the treatment of elderly patients
(age>or=70 years) with non-small cell lung cancer. Clin Oncol (R
Coll Radiol). 20:142–147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kim A, Fall P and Wang D: Palliative care:
Optimizing quality of life. J Am Osteopath Assoc. 105(Suppl 5):
S9–S14. 2005.PubMed/NCBI
|
|
9.
|
Renouf D, Kennecke H and Gill S: Trends in
chemotherapy utilization for colorectal cancer. Clin Colorectal
Cancer. 7:386–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lee Y, Kim SH, Han JY, Kim HT, Yun T and
Lee JS: Early neutrophil-to-lymphocyte ratio reduction as a
surrogate marker of prognosis in never smokers with advanced lung
adenocarcinoma receiving gefitinib or standard chemotherapy as
first-line therapy. J Cancer Res Clin Oncol. 138:2009–2016. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Templeton AJ, Ace O, McNamara MG,
Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A,
Tannock IF and Amir E: Prognostic role of platelet to lymphocyte
ratio in solid tumors: A systematic review and meta-analysis.
Cancer Epidemiol Biomarkers Prev. 23:1204–1212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Aliustaoglu M, Bilici A, Seker M, Dane F,
Gocun M, Konya V, Ustaalioglu BB and Gumus M: The association of
pre-treatment peripheral blood markers with survival in patients
with pancreatic cancer. Hepatogastroenterology. 57:640–645.
2010.PubMed/NCBI
|
|
16.
|
Azab B, Bhatt VR, Phookan J, Murukutla S,
Kohn N, Terjanian T and Widmann WD: Usefulness of the
neutrophil-to-lymphocyte ratio in predicting short- and long-term
mortality in breast cancer patients. Ann Surg Oncol. 19:217–224.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kishi Y, Kopetz S, Chun YS, Palavecino M,
Abdalla EK and Vauthey JN: Blood neutrophil-to-lymphocyte ratio
predicts survival in patients with colorectal liver metastases
treated with systemic chemotherapy. Ann Surg Oncol. 16:614–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Sarraf KM, Belcher E, Raevsky E, Nicholson
AG, Goldstraw P and Lim E: Neutrophil/lymphocyte ratio and its
association with survival after complete resection in non-small
cell lung cancer. J Thorac Cardiovasc Surg. 137:425–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of
neutrophils to lymphocytes is associated with patient prognosis in
advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Bast RC Jr, Klug TL, St John E, Jenison E,
Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker
L, et al: A radioimmunoassay using a monoclonal antibody to monitor
the course of epithelial ovarian cancer. N Engl J Med. 309:883–887.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Prommer E: Guidelines for the use of
palliative chemotherapy. AAHPM Bulletin. 5:2–13. 2004.
|
|
24.
|
McIllmurray M: Symptom management. Oxford
Textbook of Palliative Medicine. Doyle D, Hanks G, Cherny NI and
Calman K: (3rd). (New York, NY). Oxford University Press. 229–239.
2004.
|
|
25.
|
Lin X, Li W, Lai J, Okazaki M, Sugimoto S,
Yamamoto S, Wang X, Gelman AE, Kreisel D and Krupnick AS: Five-year
update on the mouse model of orthotopic lung transplantation:
Scientific uses, tricks of the trade, and tips for success. J
Thorac Dis. 4:247–258. 2012.PubMed/NCBI
|
|
26.
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Jackson JR, Seed MP, Kircher CH,
Willoughby DA and Winkler JD: The codependence of angiogenesis and
chronic inflammation. FASEB J. 11:457–465. 1997.PubMed/NCBI
|
|
28.
|
McMillan DC, Canna K and McArdle CS:
Systemic inflammatory response predicts survival following curative
resection of colorectal cancer. Br J Surg. 90:215–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Assoian RK and Sporn MB: Type beta
transforming growth factor in human platetlets: Release during
platelet degranulation and action on vascular smooth muscle cells.
J Cell Biol. 102:1217–1223. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Dubernard V, Arbeille BB, Lemesle MB and
Legrand C: Evidence for an alpha-granular pool the cytoskeletal
protein alpha-actinin in human platelets that redistributes with
the adhesive glycoprotein thrombospondin-1 during the exocytotic
process. Arterioscler Thromb Vasc Biol. 17:2293–2305. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kaplan KL, Broekman MJ, Chernoff A,
Lesznik GR and Drillings M: Platelet alpha-granule proteins:
Studies on release and subcellular localization. Blood. 53:604–618.
1979.PubMed/NCBI
|
|
32.
|
Qian X and Tuszynski GP: Expression of
thrombospondin-1 in cancer: A role in tumor progression. Proc Soc
Exp Biol Med. 212:199–207. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Dabrow MB, Francesco MR, McBrearty FX and
Caradonna S: The effects of platelet-derived growth factor and
receptor on normal and neoplastic human ovarian surface epithelium.
Gynecol Oncol. 71:29–37. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim
YT and Lee K: Pre-treatment neutrophil to lymphocyte ratio is
elevated in epithelial ovarian cancer and predicts survival after
treatment. Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Asher V, Lee J, Innamaa A and Bali A:
Preoperative platelet lymphocyte ratio as an independent prognostic
marker in ovarian cancer. Clin Transl Oncol. 13:499–503. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Matsuyama R, Reddy S and Smith TJ: Why do
patients choose chemotherapy near the end of life? A review of the
prospective of those facing death from cancer. J Clin Oncol.
24:3490–3496. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im
SA, Kim TY, Bang YJ and Heo DS: Aggressiveness of cancer-care near
the end-of-life in Korea. Jpn J Clin Oncol. 38:381–386. 2008.
View Article : Google Scholar : PubMed/NCBI
|
